🇺🇸 FDA
Patent

US 10077446

Glucan-encapsulated siRNA for treating type 2 diabetes mellitus

granted A61KA61K31/713A61P

Quick answer

US patent 10077446 (Glucan-encapsulated siRNA for treating type 2 diabetes mellitus) held by The United States of America as Represented by the Secretary, Dept. of Health and Human Services expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary, Dept. of Health and Human Services
Grant date
Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/713, A61P, A61P3/10